Clinical outcomes following high-dose-rate surface applicator brachytherapy for angiosarcoma of scalp and face.
HDR brachytherapy
angiosarcoma
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
10
11
2020
accepted:
07
01
2021
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
27
4
2021
Statut:
ppublish
Résumé
Angiosarcoma is a sub-type of soft tissue sarcoma, often presenting as a multifocal or diffuse disease process with poor prognosis. This study presents outcomes of a single institution cohort of patients with angiosarcoma of the scalp and face following treatment with multimodality therapy, including high-dose-rate surface applicator (HDR-SA) brachytherapy, and represents the largest cohort utilizing this therapeutic approach. Twenty patients with primary or recurrent angiosarcoma of the face or scalp were treated with HDR-SA brachytherapy between 2003-2018, with clinical characteristics and outcomes collected from medical records and used to identify prognostic features. Median follow-up was 45 months. Patients treated with HDR-SA brachytherapy had a 4-year local control rate of 63%, a 4-year progression-free survival (PFS) rate of 20%, and a 4-year overall survival rate of 54%. Disease features associated with worse loco-regional control (LRC) included location on the scalp (vs. face, Local control rates following HDR-SA brachytherapy for scalp or face angiosarcoma are moderate and similar to what is described in the literature using a variety of local control treatment modalities. Smaller tumors and those involving the face rather than scalp had better outcomes. PFS rates were poor and there is a pressing need for treatment intensification and novel therapeutic options.
Identifiants
pubmed: 33897791
doi: 10.5114/jcb.2021.105285
pii: 43832
pmc: PMC8060956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
172-178Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2021 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Head Neck. 2011 May;33(5):661-7
pubmed: 20960566
Sarcoma. 2020 Aug 25;2020:7615248
pubmed: 32908445
Otolaryngol Head Neck Surg. 2008 Oct;139(4):519-24
pubmed: 18922337
Mol Clin Oncol. 2017 Mar;6(3):334-340
pubmed: 28451409
Cancer. 2003 Oct 15;98(8):1716-26
pubmed: 14534889
Ann Diagn Pathol. 2011 Apr;15(2):93-7
pubmed: 21190880
JAMA Otolaryngol Head Neck Surg. 2015 Apr;141(4):335-40
pubmed: 25634014
Cancer. 1996 Jun 1;77(11):2400-6
pubmed: 8635113
Radiother Oncol. 2009 May;91(2):255-60
pubmed: 18954915
Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):153-60
pubmed: 8365936
Med Dosim. 1989;14(2):129-31
pubmed: 2504182
J Contemp Brachytherapy. 2019 Aug;11(4):337-342
pubmed: 31523234
Ann Plast Surg. 2008 Oct;61(4):399-403
pubmed: 18812710
Radiat Oncol J. 2016 Dec;34(4):313-321
pubmed: 27951625
Head Neck. 2017 Feb;39(2):380-386
pubmed: 27507124
Surg Oncol. 2018 Dec;27(4):A3-A8
pubmed: 30237037
Cureus. 2019 Jul 25;11(7):e5236
pubmed: 31555498
Head Neck. 2017 Jun;39(6):1205-1211
pubmed: 28398688
J Med Radiat Sci. 2018 Mar;65(1):39-47
pubmed: 28755441
Lancet Oncol. 2010 Oct;11(10):983-91
pubmed: 20537949